Lakefront Biotherapeutics (LKFT) Cash from Operations (2015 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Cash from Operations of 110766587.45 for Q1 2026, down 144.96% year-over-year from 246372121.32 in Q1 2025, and down 24.83% quarter-over-quarter from 88732709.04 in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Cash from Operations (2015 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Cash from Operations for 11 consecutive years, with 110766587.45 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 144.96% year-over-year to 110766587.45; the TTM figure through Mar 2026 stood at 348656773.56 (up 13.69% YoY), while the FY2025 annual figure was 358410162.22, up 19.62% from the prior year.
- Cash from Operations fell to 110766587.45 in Q1 2026 per LKFT's latest filing, from 88732709.04 in the prior quarter.
- Across five years, Cash from Operations topped out at 45218408.29 in Q1 2025 and bottomed at 183503731.62 in Q4 2022.
- Historically, Cash from Operations has averaged 106749530.6 across 5 years, with a median of 104216123.97 in 2023.
- Annual changes were most pronounced in 2025 — Cash from Operations soared 69.1% — and 2026, when it sank 144.96%.
- Lakefront Biotherapeutics' Cash from Operations stood at 183503731.62 in 2022, then soared by 40.89% to 108473033.8 in 2023, then increased by 4.18% to 103939068.79 in 2024, then gained by 14.63% to 88732709.04 in 2025, then retreated by 24.83% to 110766587.45 in 2026.
- Business Quant data shows LKFT's Cash from Operations at 110766587.45 in Q1 2026, 88732709.04 in Q4 2025, and 45218408.29 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -96.88 Mn |
| Dec 31, 2025 | -55.25 Mn |
| Mar 31, 2025 | -40.61 Mn |
| Dec 31, 2024 | -63.44 Mn |
| Mar 31, 2024 | -133.01 Mn |
| Dec 31, 2023 | -436.80 Mn |
| Mar 31, 2023 | -101.83 Mn |
| Dec 31, 2022 | -510.68 Mn |
| Mar 31, 2022 | -69.55 Mn |
| Dec 31, 2021 | -576.36 Mn |
| Jun 30, 2021 | -98.66 Mn |
| Mar 31, 2021 | -146.21 Mn |
| Dec 31, 2020 | -509.51 Mn |
| Jun 30, 2020 | -155.26 Mn |
| Mar 31, 2020 | -76.03 Mn |
| Dec 31, 2019 | -132.98 Mn |
| Sep 30, 2019 | 3.86 Bn |
| Jun 30, 2019 | -78.70 Mn |
| Mar 31, 2019 | -81.49 Mn |
| Dec 31, 2018 | -162.61 Mn |